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SUMMARY
Homeobox genes are known to be key factors in
leukemogenesis. Although the TALE family homeo-
domain factor Meis1 has been linked to malignancy,
a role for MEIS2 is less clear. Here, we demonstrate
that MEIS2 is expressed at high levels in patients
with AML1-ETO-positive acute myeloid leukemia
and that growth of AML1-ETO-positive leukemia de-
pends on MEIS2 expression. In mice, MEIS2 col-
laborates with AML1-ETO to induce acute myeloid
leukemia. MEIS2 binds strongly to the Runt domain
of AML1-ETO, indicating a direct interaction between
these transcription factors. High expression of
MEIS2 impairs repressive DNA binding of AML1-
ETO, inducing increased expression of genes such
as the druggable proto-oncogene YES1. Collectively,
these data describe a pivotal role for MEIS2 in AML1-
ETO-induced leukemia.
INTRODUCTION
Aberrant expression of clustered homeobox genes, or HOX
genes, is a molecular hallmark of acute myeloid leukemia
(AML), and many experimental studies have proven that dysre-
gulated expression of this highly conserved family of tran-
scription factors is a key factor in leukemia development (Alharbi
et al., 2013; Argiropoulos et al., 2007; Jung et al., 2015; McGoni-
gle et al., 2008; Spencer et al., 2015). Besides HOX genes, non-
clustered homeobox genes, such as the ParaHox gene CDX2,
have been shown to play an essential role in leukemogenesis
(Faber et al., 2013; Lengerke and Daley, 2012; Rawat et al.,
2012), as have members of the three-amino-acid-loop extension
(TALE) superfamily,MEIS1 and PBX1 (Argiropoulos et al., 2007).
The TALE superfamily is characterized by three highly conserved
additional residues, proline-tyrosine-proline, in the first loop re-
gion of the homeodomain (B€urglin, 1997). So far, three functional
Meis genes have been identified (Meis1, Meis2, and Meis3).
MEIS1 and MEIS2 show 82% homology at the amino acid level.
Homology is particularly high within the homeodomain and in a
second conserved domain, the homothorax homology domain
(Hth) (Moens and Selleri, 2006). There is a rich body of evidence
arguing that Meis1 plays a pivotal role in normal and malignant
hematopoiesis. Murine transplantation models clearly showed
that Meis1 collaborates with native Hox genes such as HoxA9
and HoxA10 and multiple NUP98-HOX fusion genes in inducing
AML (Kroon et al., 1998; Pineault et al., 2003; Thorsteinsdottir
et al., 2001). Furthermore, MEIS1 and multiple HOX genes are
aberrantly expressed in a variety of human AML genotypes
such as NPM1 mutated cytogenetically normal (CN)-AML or
AML with complex karyotype (Kawagoe et al., 1999; Rawat
et al., 2008). Interestingly, to date, MEIS1 is the only MEIS family
member to be implicated in normal or leukemic hematopoiesis.
In this report, we characterize MEIS2 as a potent oncogene in
AML1-ETO (AE)-positive AML.
RESULTS
The Homeobox Gene MEIS2 Is Aberrantly Expressed in
Patients with AE-Positive AML
Because there are few reports on the expression and function of
MEIS2 in AML, expression of this gene was evaluated in a large
cohort of patients with AML and normal CD34+ bone marrow
(BM) cells by real-time qPCR (Table S1). Strikingly, MEIS2
expression in AE-positive AML was significantly higher than
in PML-RARA and inv(16) positive cases (n = 11) (p < 0.0001)
(Figure 1A). There was also high expression in CN-AML, inde-
pendent of the NPM1 mutational status, an AML genotype
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previously associated with elevated homeobox gene expres-
sion in contrast to AE-positive AML (n = 10). Importantly, the ma-
jority AE-positive AML cases showed significantly on average
22.3-fold-higher MEIS2 transcript levels (p < 0.005) compared
to normal human CD34+ BM samples (Figure 1A). Furthermore,
MEIS2 was highly expressed in CD34+/CD38 leukemic stem
cell (LSC) candidates isolated from AE-positive cases (n = 3),
whereas no expression of this gene was detectable in four
of five samples of the corresponding normal counterpart (Fig-
ure1B). Importantly,MEIS2protein expressioncould be validated
in representative t(8;21)-positive patients at levels comparable to
normal human cord blood cells (Figure S1A).
In summary, these data indicate that AE-positive AML is
characterized by aberrant expression of MEIS2 in all leukemic
compartments, including the most primitive CD34+/CD38
compartment associated with LSC activity.
MEIS2 Collaborates with AE in Inducing AML
To test whether aberrant expression ofMEIS2 is of any functional
relevance in human AML, the impact of small hairpin RNA
(shRNA)-mediated MEIS2 depletion in the AE-positive cell lines
SKNO-1 or Kasumi-1 was analyzed. Knockdown of MEIS2 by
three independent shRNA constructs in vitro resulted in a sig-
nificant reduction in proliferation and colony formation that was
reflected in a statistically significant increase in the proportion
of cells in G0/G1phase and also an increase in cells expressing
the differentiation maker CD11b in SKNO-1 cells (Figures 2A–
2C and S1B–S1E). The functional relevance ofMEIS2 expression
was confirmed in a primary AE sample that showed 38% reduc-
tion in cell viability after small interfering RNA (siRNA)-mediated
suppression of MEIS2 expression in comparison to the scram-
bled control (Figure 2D).
To further validate collaboration of MEIS2 with AE, we tested
expression of Meis2 in normal murine hematopoiesis and
mimicked co-expression ofMeis2 with the AE fusion gene in hu-
man AML by retrovirally engineered co-expression of MEIS2
and AE in murine progenitor cells. In line with our findings in
normal human BM, Meis2 expression was low in hematopoietic
stem cells and absent in most samples of more differentiated
hematopoietic cells (Figure S2A). AE collaborated significantly
with MEIS2 as reflected in the colony forming unit-spleen
(CFU-S) assay, increasing the median colony number on the
spleen by 2.3-fold (p < 0.05) 12 days post-transplant compared
to mice transplanted with cells carrying AE alone (Figure S2B).
Mice transplanted with BM cells expressing constitutively AE,
MEIS2, or GFP did not develop any disease up to 500 days
post-transplantation. In contrast, mice injected with only
3.1% ± 2.3% transduced BM cells co-expressing both the AE
fusion and MEIS2 developed AML 171 days after transplanta-
tion (n = 7), with an average engraftment of 92.4% ± 0.01%
SEM and significant shortening of survival compared to the
GFP control mice, indicating collaboration of both genes in vivo.
Leukemias generated by AE and MEIS2 were transplantable
and induced disease after a short latency of 33 days in second-
ary recipients (n = 11) (Figure 3A). Examination of the peripheral
blood (PB) of diseased mice showed hyperleukocytosis, accu-
mulations of blasts, splenomegaly, and severe multi-organ infil-
tration with leukemic blasts, which were highly positive for
Mac1, Gr1, and c-Kit (Figures 3B, S2C, and S2D; Tables S2
and S3). According to the Bethesda criteria for hematological
neoplasms, all mice in the AE/MEIS2 arm died of AML with
maturation (Figure 3C).
In contrast to the observed synergy in leukemogenic activity
between MEIS2 and AE, MEIS2 overexpression did not shorten
disease latency when combined with the more potent AML1-
ETO9a (AE9a) gene, previously shown on its own to be able to
cause AML within 175 days (Yan et al., 2006) (Figures S2E–
S2G). This was in line with results from the CFU-S assay, which
did not show any differences in splenic colony formation be-
tween AE9a/MEIS2 and AE9a alone (Figure S2H). Of note, over-
expression of AE9a was observed to enhance endogenous
Meis2 expression 6.2-fold (±1.60 SEM) in murine BM progenitor
cells, a level of induction substantially higher than that seen
with AE alone (3.05-fold [±0.48 SEM]) (Figure S2I). Importantly,
there were no recurrent retroviral integration sites in both AE/
MEIS2- and AE9a- or AE9a/MEIS2-positive leukemias enlisted
Figure 1. MEIS2 Expression in Patients
with AML
(A) Quantification of MEIS2 expression in core
binding factor (CBF) and normal-karyotype AML.
Expression levels of MEIS2 in AML patients with
AE, PML-RARa fusions, or Inv(16), and normal
human BM CD34+ cells were determined by
qRT-PCR (relative to housekeeping gene TBP).
MEIS2 was expressed in 6/11 PML-RARAa, 11/
11 inv(16), and in 7/13 normal CD34+ samples. All
tested AE and NPMc+ (n = 5) or NPM wild-type
(WT) (n = 5) cases were positive for MEIS2
expression. Expression values are shown as
mean ± SEM. Statistical significance is indicated
(****p < 0.0001).
(B) Quantification of MEIS2 expression in
leukemic and normal hematopoiesis. Expres-
sion levels of MEIS2 of leukemic subpopulations
of patients with AE-positive AML and normal
BM subpopulations were determined by qRT-PCR (relative to housekeeping gene TBP). Bars show the mean ± SEM. *, not detectable (****p <
0.0001). MEIS2 expression in normal CD34+/CD38 (n = 1/5) and CD34+/CD38+ (n = 1/2); *, not detectable.
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in the retroviral tagged cancer genes database (RTCGD) (data
not shown).
To characterize genes and pathways differentially expressed
by overexpression of MEIS2 and AE-positive cells, we per-
formed microarray analyses 48 hr after successful gene trans-
duction in 5-fluorouracil (5-FU)-mobilized murine progenitor
cells. In comparison to the GFP control, MEIS2 with AE induced
upregulation of 75 probesets corresponding to 23 genes and
downregulation of 159 probesets corresponding to 122 genes.
In contrast to the upregulated genes, the vast majority of down-
regulated genes did not overlap between AE/MEIS2 and AE
alone (Figures S3A and S3B; Table S4). When these differentially
expressed genes between AE/MEIS2 and GFP were analyzed in
the Kyoto Encyclopedia of Genes and Genomes (KEGG)-based
pathway analysis, ‘‘cytokine-cytokine receptor interaction,’’
‘‘transcriptional misregulation in cancer,’’ and ‘‘pathways in can-
cer’’ scored among the top-five ranking categories. In a direct
comparison between AE and AE/MEIS2 BM, out of 195 differen-
tially regulated probesets referring to 145 genes, 29 probesets
(12 genes) were upregulated and 166 probesets (80 genes)
were downregulated (Table S4). Interestingly, Hoxa genes such
as Hoxa5, Hoxa7, Hoxa9, and Hoxa10 were downregulated
in AE and AE/MEIS2 compared to the empty vector. This was
further validated by qRT-PCR, indicating that the leukemogenic-
ity of AE/MEIS2 does not depend on upregulation of oncogenic
Hoxa genes (Figures S3C and S3D). Gene set enrichment anal-
ysis (GSEA) analysis for oncogenic signature (MsigDB version
5.0) showed enrichment for gene sets such as ‘‘JAK2’’ and
‘‘PTEN’’ in AE/MEIS2 versus AE alone (Figure S3E; Table S4).
Consistent with the finding that MEIS2 did not increase leuke-
mogenicity of AE9a, RNA-seq of leukemic BM showed a close
overlap in gene expression between AE9a and AE9a/MEIS2,
indicating that adding of MEIS2 to the leukemogenic truncated
AE9a does not induce gross changes in themolecular phenotype
of AE9a-positive leukemias (Figures S3F and S3G).
Taken together, these data indicate that MEIS2 functionally
collaborates with AE in AML.
MEIS2 Binds to AE
To understand the mechanism of AE-MEIS2 collaboration, we
first sought to identify domains of the fusion gene that may
be critical for collaboration between AE and MEIS2 using the
CFU-S assay as readout for growth-promoting activity (Figures
S4A and S4B). Only the inactivating point mutation in the Runt
Figure 2. Impact of shRNA-Mediated Lentiviral Knockdown ofMEIS2 on t(8;21)-Positive AMLCell Lines and a t(8;21)-Positive Patient Sample
(A and B) Impact of knockdown (KD) ofMEIS2 compared to SCR control on (A) proliferation (n = 3 for SKNO-1 with KD of 31.85 ± 8.4 SEM for sh44, 43.8 ± 6.8 SEM
for sh58, and 19.5 ± 2.78 SEM for sh60, respectively, and 42.7 ± 7.1 SEM for sh44, 30.5 ± 4.4 SEM, for sh58 and 30.9 ± 6.3 SEM for sh60, respectively) and (C)
colony formation (n = 3 for Kasumi-1). Significance was calculated by two-way ANOVA (****p < 0.0001; ***p = 0.001; *p = 0.005).
(D) Impact of siRNA-mediated knockdown of MEIS2 in a diagnostic, previously untreated patient sample having, as a sole cytogenetic abnormality, the trans-
location t(8;21) (no. 62 in Table S1) on cell number compared to SCR control (n = 1 in technical triplicates). Average knockdown efficiency was 54.2%; cell viability
was measured 72 hr after siRNA induction.
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domain, not deletion of the NHR1 or C-terminal stretch, reduced
collaboration between MEIS2 and the fusion gene, indicating
that DNA binding properties are crucial for AE-MEIS2 leukemo-
genic collaboration. There was a trend that MEIS2 could further
enhance CFU-S activity of the C-terminally truncated D540 AE
construct that contains the TAF/NHR1 domain and lacks the
zinc-finger domains, previously shown to have similar activity
as the wild-type AE (Westendorf et al., 1998) (Figure S4C). To
test for a possible direct interaction between AE and MEIS2,
co-immunoprecipitation (coIP) assays along with various other
mutants of MEIS2 (Figure S4D) were performed in HEK293 cells.
Surprisingly, strong binding of MEIS2 to the Runt domain of AE
could be documented (Figures 4A and 4B). Additional experi-
ments showed that AE9a is also able to strongly bind to MEIS2
(Figure S4E) and that the N-terminal region (amino acids [aa]
D1–68 or 69–470) of MEIS2 is critical for binding to the Runt
domain of AE and AE9a (Figures 4C, 4D, S4E, and S4F). The
binding of MEIS2 to AEwas validated in a human leukemic back-
ground by performing immunoprecipitation for ETO and western
blotting forMEIS2 in theAE-positive humancell lineSKNO-1 (Fig-
ure S4G). To test whether hematopoietic activity of MEIS2 de-
pends on binding to AE, we generated a mutant with deletion of
1–68 aa N-terminally (MEIS2(69–470)), which has lost its binding
capacity to the fusion gene (Figure 4D). In contrast to the wild-
type MEIS2, which induced significantly more colonies in collab-
oration with AE than AE alone, MEIS2(69–470) plus AE failed to
increase colony numbers compared to AE alone. This could
be re-confirmed in secondary re-plating assays, which also
showed a significant loss of activity of the AE/MEIS2 (69–470)
combination compared to AE/MEIS2. Similarly, at the level
of CFU-S, AE/MEIS2 increased spleen colony numbers signifi-
cantly compared to AE alone in contrast to the AE/MEIS2
(69–470) combination. This was further confirmed in the more
sensitive DCFU-S assay, which showed a lack of collabora-
tion between AE andMEIS2 (69–470) (Figures S4H–S4J). Collec-
tively, these data provide evidence that MEIS2 is able to directly
interact with themost frequent fusion gene in AML and that bind-
ing to AE is critical for its full collaborative activity in the CFU-S
assay.
MEIS2 Alters Target Gene Binding of AE
ToanalyzewhetherMEIS2expression levels impactAEDNAbind-
ing properties, chromatin immunoprecipitation (ChIP) sequencing
was performed in the human AE-positive Kasumi cell line after
shRNA-mediated MEIS2 knockdown (shMEIS2-44) compared to
the scrambled control, using an AE fusion-specific antibody
(Martens et al., 2012). Successful enrichment for AE target genes
by the antibody used was first validated by ChIP qPCR for known
specific binding partners of AE such as SPI1, OGG1, FUT7, and
NFE2, each of which showed substantial enrichment (showing
anup to18-fold) (FiguresS5AandS5B). Inaddition,motif analyses
of the AE binding sites in the ChIP-seq revealed enrichment for
both the RUNX1 and ETS1 target sites as previously reported
(Martens et al., 2012) in both experimental arms, comprising
between 35% and 42% of all target regions, as well as the pres-
ence of weaker motifs with 44.32% and 65.8% for scrambled
(SCR) and shMEIS2, respectively (Figures S5C–S5F; Table S5).
As we observed increased binding of AE to RUNX1 after MEIS2
knockdown, changes in expression of RUNX1 were tested in the
t(8;21)-positive cell lines SKNO-1 and Kasumi afterMEIS2 deple-
tion: however, knockdown induced no major change of RUNX1
expression in both cell lines (n = 3) (data not shown).
Figure 3. Co-expression of MEIS2 and AML1-ETO Induces AML in Mice
(A) Survival plot of mice transplantedwith AE andMEIS2. Kaplan-Meier survival curves of mice transplantedwith BMcells expressing AML1-ETO (AE), MEIS2, the
empty GFP control vector, or AE/MEIS2. Survival of secondary recipients transplanted with BM of diseased primary AE/MEIS2 mice is shown in addition. Log-
rank Mantle-Cox test was used to calculate the statistical significance as indicated (**p < 0.005; ****p < 0.0001; ***p = 0.0001; **p = 0.001).
(B and C) Dot plot of a representative leukemic AE/MEIS2 mouse (B) and histological analysis of different organs (C). Immunophenotyping and histology of BM
and PB of a representative mouse diagnosed with AML is given (mouse no. 10; Table S3). Samples were gated for GFP-positive cells. MPO, myeloperoxidase;
CAE, N-acetyl-chloroacetate esterase. Histology pictures are magnified 4003. Scale bar, 50 mm.
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At a cutoff of R10-fold with a FDR rate threshold of 0.001
and a FDR effective Poisson threshold of 0, a total of 13,003
high-confidence DNA binding regions for AE with or without
expression of shMEIS2 were detectable. Of note, knockdown
of MEIS2 increased the number of AE binding sites compared
to the control by >2-fold. In addition, knockdown of the
MEIS2 gene induced >7,900 unique AE binding sites, indicating
gross changes in the DNA binding behavior of the fusion gene
after MEIS2 depletion (Figure 5A). When we focused on the pro-
moter regions (defined as binding regions 1 kb upstream and
100 bp downstream of the transcription start site), AE still bound
to significantly more DNA sites after MEIS2 knockdown, with
>1,100 unique binding sites compared to the control (Figure 5B;
Table S4). The higher number of AE DNA binding sites after
MEIS2 depletion was a consistent characteristic throughout
the differentially annotated DNA regions (Figure 5C). Among
those genes that showed substantial increase of AE binding af-
ter MEIS2 knockdown were IGFBP7, mir-4442, OGG1, RUNX1,
and WT1. A smaller proportion of genes showed decreased
AE binding after MEIS2 depletion, such as mir-145, NDUFA4,
and KRAS (Figure S6A). Other genes did not meet the above-
mentioned criteria for AE binding in the scrambled control
but met the requirements with a >10-fold increase in AE binding,
such as ASLX2, FLT3, CREB1, GSK3a, and HMGA1 (Table S6).
Of note, expression of MEIS2 decreased after AE shRNA-
mediated knockdown in SKNO-1 cells, although there was no
documented binding of AE to the MEIS2 promoter (Figures
S6B and S6C).
Thus, these data demonstrated that high MEIS2 expression is
associated with a reduction of AE binding to DNA targets and,
vice versa, that knockdown of MEIS2 increases AE binding sites.
Furthermore, the data show that AE binds to a distinct and
unique set of DNA sites in human AML cells whenMEIS2 is highly
expressed.
Figure 4. Co-immunoprecipitation Assays on AE and MEIS2 Interaction in HEK293 Cells
(A) Immunoprecipitation (IP) of FLAG-AE and western blot using anti-FLAG and anti-ETO (for AE) and anti-GFP (for MEIS2) antibodies, respectively. Interaction of
MEIS2 with AE is shown in lane 5.
(B) IP of FLAG-RUNT and FLAG-AE and western blot using anti-FLAG (for RUNT and AE) and anti-GFP (for MEIS2), antibodies, respectively. MEIS2 interacts with
AE and to the RUNT domain of AE (lane 3). *Immunoglobulin G (IgG) heavy chains (in C heavy and light IgG chains).
(C and D) Additional mutants of MEIS2 were generated to map the interacting domain of full-length AE and RUNT with MEIS2. WT MEIS2 and all the mutants
interacted strongly with AE and RUNT, except the N-terminally deleted mutants D1–68 (aa 49–470) and D1–274 (aa 275–470).
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High Expression of MEIS2 Is Associated with Loss of AE
Binding to the YES1 Promoter Region and Increased
YES1 Expression
To correlate AE target gene binding with expression levels, RNA-
seq was performed in parallel to ChIP sequencing (ChIP-seq) for
the same samples in duplicates. Genes were considered as
differentially expressed when the difference in FPKM (fragments
per kilobase per millions reads) was significant at a p value of
0.05, with a false discovery rate (FDR) of 0.05. First, differen-
tially expressed genes were analyzed independent of AE target
binding: 868 genes were differentially expressed between
Kasumi cells transduced with the MEIS2 shRNA versus scram-
bled control (Table S4). KEGG analysis showed changes in the
expression of genes belonging to the categories ribosomes, ly-
sosomes, and adherence junction (Tables S4 and S7). Of note,
MEIS2 knockdown induced major differences in gene expres-
sion, with an up to 2.25 log2 fold change for upregulated genes
(n = 365) and up to 9 log2 fold for downregulated genes (n = 123
genes) compared to the SCR control (Table S4).
As a second step, we correlated differentially expressed
genes with AE DNA binding. Among the genes with changes in
expression and AE binding, there were two categories. The first
showed an increase in expression accompanied by an enhanced
AE binding to their promoter region (e.g.,MPO, KIT,NUCB2, and
CD34 MYOG1). The second group showed decreased expres-
sion level parallel to increased AE binding (e.g., YES1, BCL2L1,
HMGA1, IGFBP2, and TXNIP) after MEIS2 knockdown (Table
S8). We validated these findings for selected genes and found
a significant (p < 0.05) positive correlation between expression
levels determined by RNA-seq and qRT-PCR (Figure S6D).
Therewas no decrease in the expression of the targetable recep-
tor tyrosine kinases c-Kit and FLT3 after MEIS2 knockdown as
validated by qRT-PCR. In contrast, knockdown of MEIS2
induced a substantial decrease in expression of the Src kinase
YES1 accompanied by increased AE promoter binding of this
gene (Figure 6A). This finding thus provided an intriguing gene
whose expression was strongly dependent on MEIS2 overex-
pression and whose effects were potentially druggable. Of
note, knockdown of YES1 resulted in an up to 78% reduction
in proliferation and 95% reduction in clonogenic growth in Ka-
sumi cells (Figures 6B–6D), indicating that YES1 expression is
relevant for the cell growth of this AE-positive AML cell line.
This was in line with the observation that knockdown of Yes1
in primary leukemic murine AE9a/MEIS2 cells impaired primary
clonogenic growth by, on average, 70.5% (sh84) and 71.14%
(sh152) and re-plating by 93.98% and 69.13% for the two
Figure 5. AE Binding Sites
(A) Venn diagram showing the number and overlap of all genomic AE binding sites in Kasumi-1 cells after knockdown of MEIS2 (shMEIS2-44) compared to the
SCR control.
(B) Venn diagram showing the number and overlap of genomic AE binding sites in the promoter region (the annotated peaks that are 1 kb upstream of the TSS and
100 bp downstreak of the TSS) in Kasumi-1 cells after knockdown of MEIS2 (shMEIS2-44) compared to the SCR control.
(C) Distribution of the AE binding sites in the genome (relative to RefSeq genes). TSS, transcriptional start site; TES, transcriptional end site.
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shRNAs, respectively (Figures S6F–S6H). Indeed, all AML geno-
types, including the AE-positive AML subtype showed YES1
expression as previously indicated in The Cancer Genome Atlas
(TCGA) database (Network, 2013) (Figure S6E). Next, we tested
the efficacy of pharmacological YES1 inhibition. So far, there are
no selective YES1 inhibitors available. One of the most potent
YES1 inhibitors is dasatinib, which also impairs other kinases
such as c-Src, Fyn, and Lyn (BMS-354825) (Patel et al., 2013).
The AE-positive Kasumi cell line, expressing high levels of
MEIS2, is also positive for YES1 expression and showed com-
plete loss of phosphorylation of the kinase after dasatinib treat-
ment. With a half maximal inhibitory concentration (IC50) value of
6.8 mM, dasatinib was highly efficient in impairing Kasumi cell
growth in vitro (Figures 6E and 6F). Although it has to be taken
into account that dasatinib is a multikinase inhibitor known to
target several other kinases such as Lyn, PDGFR, KIT, Lck,
Fyn, and c-Src, these data at least suggest that YES1 is an
attractive target in AE-positive AML.
All together, these data point to a regulatory network, in which
highMEIS2 expression collaborateswith AE in inducing leukemia,
involving at least in part MEIS2’s ability to strongly bind to AE and
thereby grossly change binding of AE to its target genes on a
global scale. This results in lossof repressionof proto-oncogenes,
exemplified by an increase in the expression of the YES1 kinase in
AMLcells, thereby opening avenues to link a leukemogenic liaison
between transcription factors to a druggable target.
DISCUSSION
AML characterized by the translocation t(8;21) counts for 15% of
all human AML cases and is characterized by expression of the
most frequent fusion genedetectable in patientswith this disease.
So far, theAE-positive AMLgenotypewas not associatedwith de-
regulated homeobox gene expression (Andreeff et al., 2008; Lo
et al., 2012). In this report, we nowprovide evidence that TALEho-
meobox genes are involved in AE leukemogenesis and that they
can directly interact with the fusion gene. We initiated the study
quantifying the expression of the TALE homeobox gene MEIS2
in a larger AML patient cohort and could readily demonstrate
that MEIS2 is aberrantly highly expressed not only in virtually all
AE-positive AML cases compared to normal CD34+ hematopoie-
sis but also in comparison to other core binding factor (CBF)
leukemias. The mechanism behind this observation is unclear.
Despite the gross differences in MEIS2 expression between AE
AML samples and normal CD34+ BM cells, both populations did
not show any major methylation differences at the CpG regions
of the MEIS2 promoter as determined by MassARRAY technol-
ogy, indicating that expression of this gene is not regulated by
Figure 6. YES1 Expression after MEIS2 Knockdown
(A) Expression of YES1 after MEIS2 knockdown in Kasumi cells determined by qRT-PCR and RNA-seq showing downregulation of the kinase.
(B) Percentage of YES1 knockdown in Kasumi cells.
(C) Cell growth of Kasumi cells after YES1 knockdown compared to SCR control (n = 3).
(D) Colony formation after YES1 knockdown compared to SCR control (n = 3; mean ± SEM).
(E) 23 105 Kasumi-1 cells were treated with dasatinib at different concentrations for 72 hr, resulting in an IC50 value of 6.8 mm (calculated on the basis of live cells
with probit = 5 [50% effect]; Y = 0.53 loge concentration + 0.28 sigmoid model). Bar graphs (mean ± SEM) show that dasatinib concentrations between 1,000 nm
and 10,000 nm resulted in >50% cell growth inhibition after 72 hr.
(F) IP of YES1 and western blotting for p-YES1 in Kasumi-1 cells treated with DMSO or 6.8 mm dasatinib for 72 hr, demonstrating loss of phosphorylation after
dasatinib treatment.
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methylation, at least of these CpG islands (data not shown). Inter-
estingly, published microarray data documented a significantly
and 4.3-fold (log2) increased expression ofMEIS2 after retrovirally
induced overexpression of AE in human CD34+ cord blood cells
compared to the control (expression atlas EMBL-EBI; Krejci
et al., 2008), in line with our own data showing the same observa-
tion for murine progenitor cells, whereas in the human setting, a
reduction of MEIS2 expression after knockdown of AE was only
observed in the t(8;21)-positiveSKNO-1 cell line andnot inKasumi
cells (data not shown). The mechanism of this is not clear, as we
did not see any major binding of AE to the MEIS2 region, as also
described by Ptasinska et al. (Ptasinska et al., 2012).
Functional relevanceof highMEIS2 expression in collaboration
with AE could be clearly demonstrated by knockdown in human
AML cells and in the BM transplantation assay, in which only
MEIS2, in collaboration with AE, induced leukemia in contrast
to MEIS2 or AE alone, as shown by us and several other groups
(deGuzman et al., 2002; Fenske et al., 2004; Licht, 2001; Schessl
et al., 2005). However, in our model, the latency time until devel-
opment toAMLwas long,with amedian timeof 171daysuntil dis-
ease post-transplant. The long latency suggests that MEIS2 in
concert with the human full-length AE fusion gene needs addi-
tional partners. To test how this homeobox gene might function-
ally interconnect with AE, we analyzed binding between the two
proteins and surprisingly found strong binding between MEIS2
and AE. Interaction between endogenous MEIS2 and AE could
be re-confirmed in the human AML SKNO-1 cell line. These re-
sults thus implicate a previously unrecognized direct interaction
between AE and MEIS2 in human AML. An important question
is whether direct binding to AE is relevant for the collaboration
betweenMEIS2 and AE. To address this, we generated a mutant
that lost binding to AE. Importantly, this construct showed
reduced hematopoietic activity compared to the full-length
protein. MEIS2 was also highly expressed in AML cases with
NPM1 mutation or normal karyotype with an NPM1 wild-type
protein, and shRNA-mediated knockdown of MEIS2 impaired
growth in a panel of AML cell lines harboring, among others,
NPM1mutation or aMLL fusion (data not shown). Thismight indi-
cate that high MEIS2 expression contributes to leukemogenesis
in other AML genotypes. It will be important in future work to
analyze this in more detail and to understand possible AE-
independent mechanisms of MEIS2 leukemogenicity. We also
tested binding of MEIS2 to the truncated AE9a oncogene and
proved thatMEIS2 is also able to bind strongly to this AE isoform.
However, we did not see acceleration of AE9a induced disease
by MEIS2 co-expression, in line with published data demon-
strating rapid onset of leukemia by AE9a alone in contrast to
the full-length AE fusion (Yan et al., 2006). Complex formation be-
tween TALE homeobox genes such asMeis1 and Pbx1 has been
described and is essential for mediating Hoxa9 leukemogenicity
(Kroon et al., 1998; Shen et al., 1999), but so far, there are no re-
ports on complex formation betweenTALEhomeoboxgenes and
the AE fusion gene.With regard to AE, the fusion genemight have
a completely different DNA occupancy when interacting with
MEIS proteins. Indeed, we could demonstrate that AE changes
its DNA binding properties significantly after shRNA-mediated
MEIS2 knockdown in human AML cells. According to the ChIP-
seq data presented in this work, AE DNA binding occupancy in
AML cells was substantially reduced when MEIS2 was highly
expressed. Conversely, MEIS2 knockdown resulted in a gross
and>100% increase in thenumber ofAEbinding sites, accompa-
nied by a significant impairment of AML cell growth. This sug-
gests thatMEIS2might promote AE-associated leukemogenesis
by impairing or restricting binding of a repressive AE complex to
proto-oncogenes, resulting in a critical increase of potentially
oncogenic AE targets (Ptasinska et al., 2012). This increase in
AE binding was observed for several known genes involved in
cell activation, growth, and cancer such as KIT, MPO, HMGA1,
CD34, and IGFBP7 (Ptasinska et al., 2012) or YES1 andMAPK1
(Maiques-Diaz et al., 2012). However, changes in AE binding to
KIT did not result in changed expression in contrast to YES1.
This SCRSrc kinase has previously been described as one of
the keymembersof agene set ofAE targetswith anAML1binding
site, co-occupied by the histonedeacetylase 1andcharacterized
by a dramatic loss of H4 hyperacetylation marks. Interestingly,
this study classified YES1 among the target genes of AE (Mai-
ques-Diaz et al., 2012). We could also demonstrate that high
expression of MEIS2 can impair AE binding to the YES1 pro-
moter, resulting in an increased expression of this proto-onco-
gene in humanAMLcells. Additionally, knockdownofYES1abro-
gated the growth of AE-positive AML aswell as primary leukemic
BM. Unfortunately, to date, no selective YES1 kinase inhibitor is
available. Among the most potent YES1 inhibitors is dasatinib,
which also blocks other src kinases (Patel et al., 2013). Although
the data have to be interpreted with caution based on this, dasa-
tinib a highly potent blocker of growth of AE-positive cells, and
this was accompanied by dephosphorylation of the YES1 pro-
tein. Interestingly, clinical trials are ongoing in AE-positive AML
to test the efficacy of dasatinib as an addition to chemotherapy
or as a single agent (Boissel et al., 2015; Marcucci et al., 2013).
All of this illustrates that the leukemogenic collaboration of
MEIS2 and AE can be mechanistically linked to kinases, which
opens an avenue for targeting this leukemogenic liaison between
the two transcription factors by approved drugs such as
dasatinib.
Altogether, these data shed light on an unexpected leukemo-
genic crosstalk between the most frequent fusion gene in AML
and the MEIS2 homeobox gene, identifying MEIS2 as a potent
collaborative leukemogenic partner that affect DNA binding of
the most frequent fusion gene in human AML.
EXPERIMENTAL PROCEDURES
Patient Samples, Cell Lines, and Mouse Experiments
Mononuclear cells isolated from diagnostic BM or PB with AML leukemias from
92adult patientswere analyzed (n=70 for t(8;21), n=11 forPML-RARa, n =11 for
inv (16), and n= 5 forNPM-WTandNPMC+). CD34+ frombonemarrowmononu-
clear cells (BMMNCs;Lonza) (n=13) fromhealthy individualswere takenascon-
trols. Cytochemistry and cytogenetics (Table S1) were performed in all cases as
described. Cases were classified according to the French-American-British
criteria andWorld Health Organization classification (Bennett et al., 1976; Harris
etal., 1999). Thestudywasapprovedby theethicscommitteesofall participating
institutions, and informed consent was obtained from all patients before
they entered the study in accordance with the Declaration of Helsinki (http://
www.wma.net/en/30publications/10policies/b3/index.html). The t(8;21)-posi-
tive AML cell lines Kasumi-1 (all DMSZ) andSKNO-1 (kindly provided byMichael
L€ubbert, Freiburg, Germany) were used for expression analysis. Kasumi-1 and
OCI-AML3 were cultured in RPMI 1640 with 20% fetal bovine serum (FBS) and
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1% penicillin-streptomycin. SKNO-1 was cultured in RPMI 1640 medium with
10% FBS + granulocyte-macrophage colony-stimulating factor (GM-CSF)
(10 ng/ml). Mice experiments were performed in compliance with the German
Law for Welfare of Laboratory Animals and were approved by the Regierung-
spra¨sidium T€ubingen, Germany.
Co-immunoprecipitation and Western Blotting
Cell lines HEK293 (ATCC, CRL 1573) and HeLa (ATCC, CCL 2) were grown in
DMEM (Gibco) supplemented with 10% fetal calf serum (FCS), penicillin, and
streptomycin. HEK293 and HeLa cells were transfected using the Nanofectin
transfection reagent (PAA) according to the manufacturer’s instructions. For
western blotting and immunoprecipitation (IP) experiments whole-cell lysates
were prepared as described previously (Salat et al., 2008; Wacker et al., 2011).
Protein concentrations were determined using the Bradford assay method
(Bio-Rad). Details regarding coIP and western blot can be found in Supple-
mental Experimental Procedures.
ChIP-Seq and Peak Detection
Chromatin was harvested as described previously (Denissov et al., 2007). ChIP
was performed using specific antibodies to AE (Diagenode, C15310197) and
analyzed by qPCR or ChIP-seq as previously described (Martens et al.,
2012). Primers for qPCR used were as follows:
SPI1: forward, 50-GGGTAAGAGCCTGTGTCAGC-30; reverse, 50-CAGATG
CACGTCCTCGATAC-30
FUT7: forward, 50-TGAAACCAACCCTCAAGGTC-30; reverse, 50-TCACTG
GCATGAATGAGAGC-30
NFE2: forward, 50-GGTTAGCAGCATACGTGGAG-30; reverse, 50-ACGATA
CGGAGAAAACCACG-30
OGG1: forward, 50-CCACCCTGATTTCTCATTGG-30; reverse, 50-CAACCA
CCGCTCATTTCAC-30
VAV1: forward, 50-AGAAGGGTTTGAGGGCTAGG-30; reverse, 50-CTGTTA
CCAGGGCTTGGTTG-30
H2B: forward, 50-TGCATAAGCGATTCTATATAAAAGCG-30; reverse, 50-AT
AAAGCGCCAACGAAAAGG-30
MYOG: forward, 50-AAGTTTGACAAGTTCAAGCACCTG-30; reverse, 50-TG
GCACCATGCTTCTTTAAGTC-30.
Relative occupancy was calculated as fold over background, for which the
second exon of the myoglobin gene or the promoter of theH2B gene was used.
Illumina sequencing was done as previously described (Martens et al., 2010).
Briefly, end repair was performedusing the precipitatedDNAof30million cells
using Klenow and T4 PNK. A 30 protruding A base was generated using Taq po-
lymerase, and adapters were ligated. The DNA was loaded on gel and a band
corresponding to 300 bp (ChIP fragment + adapters) was excised. The DNA
was isolated, amplified by PCR, and used for cluster generation on the Illumina
genome analyzer. Fastq files were quality controlled and adaptor trimmed using
trimmgalore (Martin, 2011), andsequenceswithphredscoreof 20orhigherwere
considered fordownstreamanalysis. Sequenceswere thenaligned to thehuman
genome version hg19 using bowtie2 (Barbie et al., 2009). Peak calling and anno-
tation was done using CisGenome (Ji et al., 2008) and HOMER v3.12 (http://
homer.salk.edu/homer/ngs/peaks.html).
RNA-Seq and Analysis
RNA-seq was performed using libraries prepared by TruSeq RNA Sample
preparation Kit version 2. The samples were run on HiSeq2000. After trimming
Illumina sequencing adapters using trimm galore (Martin, 2011), high-quality
raw Fastq files (phred score of 20 or higher) were aligned using tophat and
respective RefSeq files (the human Hg19 assembly and the murine mm10
genome version). Differential expression analysis was performed using Cuf-
flinks (Trapnell et al., 2009, 2010) and R packages (Team, 2013).
ACCESSION NUMBERS
The accession numbers for the microarray, ChIP-seq, and RNA-seq (Kasumi
cell and murine leukemic BM samples) are GEO: GSE81174, GSE81321,
GSE81328, and GSE81329, respectively.
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Supplemental Information includes Supplemental Experimental Procedures,
five figures, and eight tables and can be found with this article online at
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